Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nancy Cross
Observed names:
Cross, Nancy,
N Cross,
N. Cross
Institution:
UCB Pharma (United States)
Observed institutions:
University of Manchester,
North Carolina Museum of History,
UCB Pharma (United States),
North Carolina Geological Survey,
UCB Pharma (Belgium)
OpenAlex ID:
A5005882286
Bimekizumab versus Adalimumab in Plaque Psoriasis
2021
·
Richard B. Warren
, Andrew Blauvelt
, et al.
·
New England Journal of Medicine
·
279
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
2018
·
Kim A. Papp
, Joseph F. Merola
, et al.
·
Journal of the American Academy of Dermatology
·
204
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
2022
·
Kenneth B. Gordon
, Richard G. Langley
, et al.
·
JAMA Dermatology
·
73
PDF
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
2020
·
Andrew Blauvelt
, Kim A. Papp
, et al.
·
Journal of the American Academy of Dermatology
·
66
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
2025
·
Andrew Blauvelt
, Richard G. Langley
, et al.
·
Journal of the American Academy of Dermatology
·
27
PDF
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials
2024
·
Joseph F. Merola
, Alice B. Gottlieb
, et al.
·
Dermatology and Therapy
·
18
PDF
Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo‐controlled, double‐blinded study
2024
·
Sang Woong Youn
, Seong Jin Jo
, et al.
·
The Journal of Dermatology
·
9
PDF
Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years
2026
·
Paolo Gisondi
, Boni Elewski
, et al.
·
Journal of Dermatological Treatment
·
7
PDF
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials
2024
·
Mark Lebwohl
, Joseph F. Merola
, et al.
·
Journal of the American Academy of Dermatology
·
7
PDF
27380 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial
2021
·
Andrew Blauvelt
, Jashin J. Wu
, et al.
·
Journal of the American Academy of Dermatology
·
7
Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)
2021
·
RB Warren
, A Blauvelt
, et al.
·
SKIN The Journal of Cutaneous Medicine
·
7
PDF
Ab0738 Dual Neutralisation of Interleukin (il)–17a and Il–17f With Bimekizumab in Moderate-to-severe Plaque Psoriasis: 60-week Results From a Randomised, Double-blinded, Phase 2b Extension Study
2019
·
Andrew Blauvelt
, Kim a. Papp
, et al.
·
Annals of the Rheumatic Diseases
·
5
PDF
14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2)
2020
·
Andrew Blauvelt
, Joseph F. Merola
, et al.
·
Journal of the American Academy of Dermatology
·
2
63300 Bimekizumab efficacy in patients with psoriasis and concurrent hypertension, elevated body mass index, or hyperglycemia: Long-term results from BE BRIGHT
2025
·
April Armstrong
, Steven R. Feldman
, et al.
·
Journal of the American Academy of Dermatology
·
1
Bimekizumab 3-year Efficacy in High-Impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from Five Phase 3/3b Trials
2024
·
Joseph F. Merola
, Curdin Conrad
, et al.
·
SKIN The Journal of Cutaneous Medicine
·
1
PDF
Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials
2022
·
Mark Lebwohl
, April W Armstrong
, et al.
·
SKIN The Journal of Cutaneous Medicine
·
1
PDF
Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension
2022
·
Diamant Thaçi
, Ron Vender
, et al.
·
SKIN The Journal of Cutaneous Medicine
·
1
PDF
Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial
2021
·
Bruce Strober
, Akihiko Asahina
, et al.
·
SKIN The Journal of Cutaneous Medicine
·
1
PDF
Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study
2019
·
Andrew Blauvelt
, Kim A Papp
, et al.
·
SKIN The Journal of Cutaneous Medicine
·
1
PDF
Bimekizumab Safety in Patients with Psoriasis Achieving Complete Skin Clearance: 4-year Analysis from 5 Phase 3/3b Trials
2026
·
Diamant Thaçi
, Kenneth B. Gordon
, et al.
·
SKIN The Journal of Cutaneous Medicine
PDF
Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years
2026
·
Gisondi, Paolo
, Elewski, Boni
, et al.
·
Figshare
Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study
2025
·
Yukari Okubo
, Yayoi Tada
, et al.
·
Dermatology and Therapy
PDF
Bimekizumab 4-year Efficacy in High-impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from BE BRIGHT
2024
·
Joseph F. Merola
, Alice B. Gottlieb
, et al.
·
SKIN The Journal of Cutaneous Medicine
PDF
52668 Bimekizumab efficacy and safety in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 3-year results from BE BRIGHT, a multicenter, open-label, phase 3 study
2024
·
Yukari Okubo
, Yayoi Tada
, et al.
·
Journal of the American Academy of Dermatology
PDF
Ab0416 Bimekizumab Impact on Cardiovascular Inflammation Markers in Moderate to Severe Plaque Psoriasis: Results From Phase 3 Trials
2024
·
G. Kokolakis
, R.B. Warren
, et al.
·
Annals of the Rheumatic Diseases
Show more works
View as search
Works count:
31
Citation count:
717
H-index:
7
I10-index:
6
Year
Topic
Type